A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Sponsor: AstraZeneca
This PHASE3 trial investigates Breast Cancer and is currently ongoing. AstraZeneca leads this study, which shows 22 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
22 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 17 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Amsterdam, Netherlands , Anderlecht, Belgium , Atlanta, United States , Baoding, China , Barcelona, Spain , Beijing, China , Bengbu, China , Bezannes, France , Bialystok, Poland and 130 more locations